LE135
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
LE135 is a drug which acts as a selective retinoic acid receptor β (RARβ) antagonist. It was developed in the 1990s and has been widely used for research into the function of RARβ especially its roles in cell differentiation during growth, tissue repair and embryonic development, regulation of immune system function, and development of certain forms of cancer. However, it has also been shown to act as a potent activator of the cation channels TRPV1 and TRPA1, which means caution must be applied when interpreting results which assume that it is only acting by blocking RARβ.
LE135 is a drug which acts as a selective retinoic acid receptor β (RARβ) antagonist. It was developed in the 1990s and has been widely used for research into the function of RARβ especially its roles in cell differentiation during growth, tissue repair and embryonic development, regulation of immune system function, and development of certain forms of cancer. However, it has also been shown to act as a potent activator of the cation channels TRPV1 and TRPA1, which means caution must be applied when interpreting results which assume that it is only acting by blocking RARβ.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374739518 under CC BY-SA 4.0; modifications have been made.